NAOV - NanoVibronix Inc Stock Price, Fair Value and News

0.76USD+0.04 (+5.56%)Delayed

Market Summary

USD0.76+0.04

Delayed

5.56%

NAOV Stock Price

View Fullscreen

NAOV RSI Chart

NAOV Valuation

Market Cap

2.1M

Price/Earnings (Trailing)

-0.66

Price/Sales (Trailing)

0.74

EV/EBITDA

0.38

Price/Free Cashflow

-0.71

NAOV Price/Sales (Trailing)

NAOV Profitability

Operating Margin

68.98%

EBT Margin

-111.16%

Return on Equity

-91.38%

Return on Assets

-51.36%

Free Cashflow Yield

-140.92%

NAOV Fundamentals

NAOV Revenue

Revenue (TTM)

2.9M

Rev. Growth (Yr)

160.17%

Rev. Growth (Qtr)

-21.75%

NAOV Earnings

Earnings (TTM)

-3.2M

Earnings Growth (Yr)

46.4%

Earnings Growth (Qtr)

27.68%

Breaking Down NAOV Revenue

Last 7 days

5.6%

Last 30 days

1.3%

Last 90 days

-35.6%

Trailing 12 Months

-79.5%

How does NAOV drawdown profile look like?

NAOV Financial Health

Current Ratio

2.45

NAOV Investor Care

Shares Dilution (1Y)

67.50%

Diluted EPS (TTM)

-1.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.9M	0	0	0
2023	1.1M	1.5M	1.9M	2.3M
2022	1.9M	2.0M	1.6M	752.0K
2021	612.0K	661.0K	1.0M	1.7M
2020	565.0K	571.0K	620.0K	623.0K
2019	319.5K	450.5K	497.5K	530.0K
2018	264.0K	344.0K	333.0K	317.5K
2017	224.0K	214.0K	218.0K	239.0K
2016	175.0K	198.0K	219.0K	229.0K
2015	189.0K	175.0K	161.0K	147.0K
2014	0	0	0	203.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NanoVibronix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 05, 2023	mika thomas	bought	12,500	0.25	50,000	-
Jun 15, 2022	fashek christopher m	bought	23,828	0.5957	40,000	-
Jun 14, 2022	brown stephen russell	bought	2,295	0.5739	4,000	chief financial officer
Jun 01, 2022	cassirer aurora	bought	1,380	0.69	2,000	-
Sep 29, 2020	fashek christopher m	bought	7,887	0.7887	10,000	-
Nov 20, 2019	fashek christopher m	bought	50,000	2.00	25,000	-

Which funds bought or sold NAOV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	-3.00	9.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-	1.00	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	225,809	225,809	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	15.11	-600	5,451	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	9,558	9,558	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-5.67	-12,000	35,000	-%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	sold off	-100	-122	-	-%
May 13, 2024	UBS Group AG	sold off	-100	-4,068	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-3,652	12,978	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	23.08	-1.00	14.00	-%

Are Funds Buying or Selling NAOV?

Are funds buying NAOV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NAOV

No. of Funds

Unveiling NanoVibronix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	227,009	SC 13G
Feb 16, 2021	kennedy capital management, inc.	0.0%	0	SC 13G/A
Feb 12, 2021	packer paul	8.0%	1,671,426	SC 13G/A
Feb 10, 2021	hirschman orin	3.9%	771,462	SC 13G/A
Jan 19, 2021	alpha capital anstalt	3.34%	645,723	SC 13G/A
Sep 04, 2020	armistice capital, llc	0%	0	SC 13G
Aug 27, 2020	alpha capital anstalt	9.97%	930,000	SC 13G
Feb 14, 2020	kennedy capital management, inc.	7.2%	320,682	SC 13G/A
Feb 14, 2020	hirschman orin	8.79%	352,953	SC 13G/A
Feb 14, 2020	packer paul	9.0%	378,514	SC 13G/A

Recent SEC filings of NanoVibronix Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 26, 2024	10-K/A	Annual Report
Apr 15, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Apr 09, 2024	10-K/A	Annual Report
Apr 08, 2024	10-K	Annual Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 28, 2024	8-K	Current Report
Feb 26, 2024	4	Insider Trading

Peers (Alternatives to NanoVibronix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

NanoVibronix Inc News

Latest updates

NanoVibronix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-21.8%	921,000	1,177,000	458,000	294,000	354,000	225,500	97,000	485,000	272,000	775,000	499,000	318,000	103,000	90,000	150,000	269,000	114,000	87,000	101,000	263,000	79,000
Cost Of Revenue	-41.6%	257,000	440,000	109,000	78,000	119,000	198,000	17,000	204,000	166,000	518,000	271,000	110,000	26,000	64,000	51,000	231,000	63,000	113,000	54,000	56,000	26,000
Gross Profit	-9.9%	664,000	737,000	349,000	216,000	235,000	-300,000	80,000	281,000	106,000	257,000	228,000	208,000	77,000	26,000	99,000	38,000	51,000	-26,000	47,000	207,000	53,000
Operating Expenses	-14.4%	1,232,000	1,439,000	1,019,000	1,225,000	1,290,000	1,408,000	1,004,000	1,549,000	1,218,000	2,767,000	1,096,000	1,199,000	1,391,000	1,566,000	903,000	1,506,000	958,000	1,213,000	840,000	1,103,000	2,276,000
S&GA Expenses	-29.2%	165,000	233,000	190,000	227,000	214,000	205,000	217,000	333,000	210,000	249,000	245,000	296,000	311,000	270,000	289,000	180,000	254,000	276,000	228,000	271,000	321,000
R&D Expenses	95.2%	121,000	62,000	33,000	35,000	55,000	107,000	49,000	61,000	66,000	115,000	50,000	64,000	64,000	40,000	68,000	16,000	47,000	133,000	79,000	150,000	152,000
EBITDA Margin	30.7%	-1.08	-1.55	-2.42	-3.17	-4.44	-6.74	-3.51	-5.61	-5.54	-8.31	-12.42	-10.41	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	33,000	35,000	33,000	34,000	-	-	-	-	-	-	-	-	24,000	123,000	-	-	5,000	5,000	-2,000	7,000
Income Taxes	-36.4%	7,000	11,000	3,000	13,000	2,000	-3,000	15,000	16,000	7,000	-55,000	70,000	-4,000	21,000	22,000	-20,000	4,000	9,000	-37,000	2,000	6,000	12,000
Earnings Before Taxes	27.6%	-581,000	-802,000	-724,000	-1,061,000	-1,095,000	-2,062,000	-940,000	-1,286,000	-1,125,000	-2,529,000	-6,605,000	-220,000	-4,896,000	-984,000	-942,000	-1,473,000	-912,000	-1,230,000	-813,000	-1,101,000	-2,667,000
EBT Margin	31.1%	-1.11	-1.61	-2.60	-3.40	-4.74	-7.20	-3.61	-5.68	-5.62	-8.41	-12.58	-10.65	-	-	-	-	-	-	-	-	-
Net Income	27.7%	-588,000	-813,000	-727,000	-1,074,000	-1,097,000	-2,059,000	-955,000	-1,302,000	-1,132,000	-2,474,000	-6,675,000	-216,000	-4,917,000	-1,006,000	-922,000	-1,477,000	-921,000	-1,193,000	-815,000	-1,107,000	-2,679,000
Net Income Margin	30.9%	-1.12	-1.63	-2.85	-3.57	-4.77	-7.24	-3.60	-5.70	-5.63	-8.43	-12.69	-10.68	-	-	-	-	-	-	-	-	-
Free Cashflow	-18.1%	-580,000	-491,000	-682,000	-1,229,000	-1,201,000	-1,330,000	-1,966,000	-1,999,000	-1,741,000	-863,000	-635,000	-1,916,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.6%	6,235	6,674	7,361	3,831	4,811	5,879	5,210	6,542	7,663	8,622	9,666	6,832	8,603	8,229	4,102	1,009	1,121	2,036	3,070	3,107	817
Current Assets	-8.4%	5,945	6,487	7,168	3,614	4,565	5,609	4,989	6,309	7,390	8,342	9,425	6,584	8,357	7,970	3,904	765	914	1,838	2,847	2,889	452
Cash Equivalents	-100.0%	-	3,283	3,787	253	1,512	2,713	1,972	3,944	5,990	7,737	8,599	5,672	7,953	7,142	3,181	-	93.00	1,338	2,258	2,371	184
Inventory	-5.3%	2,588	2,732	3,179	3,114	2,213	2,175	1,553	928	355	175	201	205	173	145	109	148	111	121	104	102	141
Net PPE	14.3%	8.00	7.00	7.00	7.00	7.00	7.00	8.00	7.00	5.00	5.00	6.00	5.00	5.00	4.00	2.00	3.00	3.00	4.00	5.00	6.00	6.00
Liabilities	1.7%	2,731	2,686	2,671	2,666	2,608	2,646	2,056	2,408	2,402	2,309	955	2,668	4,256	5,835	835	1,793	623	688	840	1,172	1,286
Current Liabilities	-1.1%	2,427	2,454	2,392	2,370	2,289	2,316	1,715	2,053	2,007	1,903	266	391	876	2,902	364	1,250	352	409	522	865	702
Shareholder's Equity	-12.1%	3,504	3,988	4,690	1,165	2,200	3,233	3,154	4,134	5,261	6,313	8,711	4,164	4,347	2,394	3,267	-	498	1,347	2,230	1,935	-
Retained Earnings	-0.9%	-66,684	-66,096	-65,283	-64,556	-63,482	-62,385	-60,326	-59,371	-58,069	-56,937	-54,463	-47,788	-47,572	-42,655	-41,650	-40,728	-39,251	-38,330	-37,137	-36,322	-35,215
Additional Paid-In Capital	0.2%	70,256	70,149	70,025	65,774	65,708	65,634	63,449	63,468	63,248	63,189	63,086	51,867	51,832	44,959	44,901	39,935	39,740	39,669	39,358	38,249	34,740
Shares Outstanding	36.1%	2,784	2,046	1,842	1,662	1,662	1,641	1,400	1,400	1,400	1,400	1,305	1,224	1,209	-	-	-	-	-	-	-	-
Float	-	-	-	-	4,831	-	-	-	17,539	-	-	-	9,447,579	-	-	-	9,447,579	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-17.9%	-579	-491	-682	-1,229	-1,200	-1,331	-1,964	-1,999	-1,741	-863	-634	-1,916	-954	-1,318	-695	-483	-895	-1,032	-1,113	-792	-937
Share Based Compensation	-13.7%	107	124	36.00	66.00	67.00	67.00	-19.00	220	86.00	268	-94.00	99.00	109	50.00	183	72.00	71.00	199	110	111	1,335
Cashflow From Investing	-Infinity%	-1.00	-	-	-	-1.00	1.00	-2.00	-	-	-	-1.00	-	-2.00	-	-	-	-	-	-	-	-
Cashflow From Financing	-	-	-	4,215	-	7.00	-	-	-	-	-	3,562	-388	1,406	5,257	4,023	-	-	112	1,000	2,979	225

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NAOV Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 921,000	$ 354,000
Cost of revenues	257,000	119,000
Gross profit	664,000	235,000
Operating expenses:
Research and development	121,000	55,000
Selling and marketing	165,000	214,000
General and administrative	946,000	1,021,000
Total operating expenses	1,232,000	1,290,000
Loss from operations	(568,000)	(1,055,000)
Interest expense	(34,000)	(34,000)
Financial expense, net	21,000	(6,000)
Loss before taxes	(581,000)	(1,095,000)
Income tax expense	(7,000)	(2,000)
Net loss	$ (588,000)	$ (1,097,000)
Basic net loss available for holders of common stock	$ (0.23)	$ (0.67)
Diluted net loss available for holders of common stock	$ (0.23)	$ (0.67)
Weighted average common stock outstanding, basic	2,510,309	1,651,936
Weighted average common stock outstanding, diluted	2,510,309	1,651,936
Comprehensive loss:
Net loss available to common stockholders	$ (588,000)	$ (1,097,000)
Change in foreign currency translation adjustments	1,000	(5,000)
Comprehensive loss available to common stockholders	$ (587,000)	$ (1,102,000)

NAOV Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 2,700,000	$ 3,283,000
Trade receivables	360,000	318,000
Prepaid expenses and other accounts receivable	297,000	154,000
Inventory	2,588,000	2,732,000
Total current assets	5,945,000	6,487,000
Noncurrent assets:
Fixed assets, net	8,000	7,000
Other assets	1,000	1,000
Severance pay fund	171,000	174,000
Operating lease right-of-use assets, net	110,000	5,000
Total non-current assets	290,000	187,000
Total assets	6,235,000	6,674,000
Current liabilities:
Trade payables	37,000	138,000
Other accounts payable and accrued expenses	2,320,000	2,265,000
Deferred licensing income, current	46,000	46,000
Operating lease liabilities, current	24,000	5,000
Total current liabilities	2,427,000	2,454,000
Non-current liabilities:
Accrued severance pay	214,000	217,000
Deferred revenue – long term	4,000	15,000
Operating lease liabilities, non-current	86,000
Total liabilities	2,731,000	2,686,000
Commitments and contingencies
Stockholders’ equity:
Common Stock of $0.001 par value – Authorized: 40,000,000 shares at March 31, 2024 and December 31, 2023, respectively; issued and outstanding: 2,784,353 and 2,046,307 shares at March 31, 2024 and December 31, 2023, respectively	2,000	2,000
Additional paid in capital	70,256,000	70,149,000
Accumulated other comprehensive income	(70,000)	(67,000)
Accumulated deficit	(66,684,000)	(66,096,000)
Total stockholders’ equity	3,504,000	3,988,000
Total liabilities and stockholders’ equity	6,235,000	6,674,000
Series C Preferred Stock [Member]
Stockholders’ equity:
Preferred stock value
Series D Preferred Stock [Member]
Stockholders’ equity:
Preferred stock value
Series E Preferred Stock [Member]
Stockholders’ equity:
Preferred stock value
Series F Preferred Stock [Member]
Stockholders’ equity:
Preferred stock value

About NanoVibronix Inc

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

CEO	Mr. Brian M. Murphy
WEBSITE	nanovibronix.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	9

NanoVibronix Inc Frequently Asked Questions

What is the ticker symbol for NanoVibronix Inc? What does NAOV stand for in stocks?

NAOV is the stock ticker symbol of NanoVibronix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NanoVibronix Inc (NAOV)?

As of Fri May 17 2024, market cap of NanoVibronix Inc is 2.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NAOV stock?

You can check NAOV's fair value in chart for subscribers.

What is the fair value of NAOV stock?

You can check NAOV's fair value in chart for subscribers. The fair value of NanoVibronix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NanoVibronix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NAOV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NanoVibronix Inc a good stock to buy?

The fair value guage provides a quick view whether NAOV is over valued or under valued. Whether NanoVibronix Inc is cheap or expensive depends on the assumptions which impact NanoVibronix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NAOV.

What is NanoVibronix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NAOV's PE ratio (Price to Earnings) is -0.66 and Price to Sales (PS) ratio is 0.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NAOV PE ratio will change depending on the future growth rate expectations of investors.